Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 234 (6), 7893-7902

Oleoylethanolamide: A Novel Pharmaceutical Agent in the Management of Obesity-An Updated Review

Affiliations
Review

Oleoylethanolamide: A Novel Pharmaceutical Agent in the Management of Obesity-An Updated Review

Payahoo Laleh et al. J Cell Physiol.

Abstract

Obesity as a multifactorial disorder has been shown a dramatically growing trend recently. Besides genetic and environmental factors, dysregulation of the endocannabinoid system tone is involved in the pathogenesis of obesity. This study reviewed the potential efficacy of Oleoylethanolamide (OEA) as an endocannabinoid-like compound in the energy homeostasis and appetite control in people with obesity. OEA as a lipid mediator and bioactive endogenous ethanolamide fatty acid is structurally similar to the endocannabinoid system compounds; nevertheless, it is unable to induce to the cannabinoid receptors. Unlike endocannabinoids, OEA negatively acts on the food intake and suppress appetite via various mechanisms. Indeed, OEA as a ligand of PPAR-α, GPR-119, and TRPV1 receptors participates in the regulation of energy intake and energy expenditure, feeding behavior, and weight gain control. OEA delays meal initiation, reduces meal size, and increases intervals between meals. Considering side effects of some approaches used for the management of obesity such as antiobesity drugs and surgery as well as based on sufficient evidence about the protective effects of OEA in the improvement of common abnormalities in people with obese, its supplementation as a novel efficient and FDA approved pharmaceutical agent can be recommended.

Keywords: GPR 119; Oleoylethanolamide; PPAR- α; TRPV1; bioactive molecules; endocannabinoids; obesity; pharmaceutical.

Similar articles

See all similar articles

LinkOut - more resources

Feedback